For Educational Use Only - Not for Detailing or Distribution
|
|
- Allen Hawkins
- 8 years ago
- Views:
Transcription
1 This document is intended for healthcare professionals practicing in the United States and may contain information that has not been approved by the FDA. It is supplied to you as a professional courtesy in response to your specific unsolicited request. Novo Nordisk does not recommend use of its products in any manner other than as described in the prescribing information. Please refer to the full prescribing information for approved product labeling and important safety information. Dilution of NovoLog Enclosed is information related to the dilution of NovoLog (insulin aspart [rdna origin] injection). Insulin Diluting Medium for NovoLog is only intended for use with NovoLog in sterile vials. Prior to use, Insulin Diluting Medium for NovoLog should be stored at 2ºC - 8ºC (36º- 46ºF) and protected from light and heat until the expiration date; do not freeze. Once mixed with NovoLog the sterile vial containing the mixture may be stored at temperatures below 30 C (86 F) for 28 days. NovoLog maintained at least 96% potency at 7 days in an in vitro study that assessed diluted NovoLog via continuous subcutaneous insulin infusion (CSII) with a NPH diluting medium. NovoLog diluted with Insulin Diluting Medium for NovoLog may not be the ideal choice for neonates with underdeveloped liver function. The decision to dilute with normal saline vs. insulin diluent should be made under the supervision of the treating physician. Insulin Diluting Medium for NovoLog Insulin Diluting Medium for NovoLog is designed for use by healthcare professionals for the dilution of NovoLog for subcutaneous injection only; this diluent is not intended for use with any other insulin product. When diluting NovoLog with Insulin Diluting Medium, the products should be combined in a sterile vial and the dilution should be performed under aseptic conditions. NovoLog may be diluted with Insulin Diluting Medium for NovoLog to a concentration equivalent to U-10 or U-50. Diluting one part NovoLog to nine parts diluent will yield a concentration one-tenth that of NovoLog (equivalent to U-10). Diluting one part NovoLog to one part diluent will yield a concentration one-half that of NovoLog (equivalent to U-50). Page 1 of 5 Last update 3/30/2010.
2 Store unused vials of Insulin Diluting Medium for NovoLog at 2ºC - 8ºC (36º- 46ºF) and protect from light and heat; do not freeze. Do not use the diluting medium if it does not appear clear and colorless, or if the cap is loose or missing. The diluted insulin preparation should not be mixed with other insulin preparations (i.e., NPH insulin) in the same syringe. The sterile vial containing the mixture of NovoLog and Insulin Diluting Medium may remain at temperatures below 30 C (86 F) for 28 days. 1 The components of the Insulin Diluting Medium and NovoLog are provided in Tables 1 and 2 for your review. Table 1. Diluent Ingredients Product Diluting Medium for NovoLog Medium Buffering agent Preservative Other ingredients Water for injection HCl and/or Sodium hydroxide (to adjust ph) Metacresol, phenol Glycerol, disodium phosphate dihydrate, water for injection to make 1 ml Table 2. NovoLog Components Product NovoLog Insulin analog Medium Buffering agent Preservative Other ingredients *Glycerol=Glycerin Insulin Aspart Water for injection HCl and/or Sodium hydroxide (to adjust ph) Metacresol, Phenol Glycerin*, zinc, disodium hydrogen phosphate dihydrate, sodium chloride, water for injection to make 1 ml Dilution of NovoLog in an Insulin Pump As stated in the prescribing information, 1 when used in an external subcutaneous insulin infusion pump, NovoLog should not be mixed with any other insulin or diluent. Novo Nordisk has not conducted clinical studies in humans evaluating the safety and efficacy of diluted NovoLog in an insulin pump, and therefore, cannot recommend this practice. Page 2 of 5
3 Jorgensen et al conducted an in vitro study that assessed diluted NovoLog via CSII with a NPH diluting medium. 2 The NPH diluting medium used in this study is no longer available; however, its ingredients and their concentrations are the same as the NovoLog diluent currently manufactured by Novo Nordisk. 3 NovoLog was diluted in concentrations of 10 U/mL and 50 U/mL and placed into 72 MiniMed 508 insulin pumps for 7 days at 98.6 o F (37 o C) with continuous oscillation. Two batches of each concentration and reference sample were tested for assay, degradation products (B28isoAsp, desamido insulin aspart and insulin aspart related impurities), high molecular weight proteins, macroscopy, ph, phenol and m-cresol. Statistical analysis showed no significant differences in degradation products between pump samples and reference samples. After 7 days, all pump samples and reference samples maintained at least 96% potency and none of the concentrations of preservatives, phenol and m-cresol, were below ~92% and ~88% of their original concentrations, respectively. In addition, macroscopy results and ph values were unaffected by in-pump-use testing. Storage of the diluted solutions for one month in sealed, sterile glass vials at 41 o F (5 o C) was shown to be acceptable. Dilution of NovoLog in Neonates It is important to note that insulin diluent may not be the ideal choice for neonates since the preservatives in the diluent can cause toxicity in an underdeveloped liver. 4 In such cases, use of normal saline solution without preservative has been studied in this population. 5,6 If NovoLog is diluted with normal saline for injection, the solution should be used promptly and should not be saved or stored, due to the lack of preservatives in the mixture. Stinging or burning at the site of injection may occur. No in vivo studies have been conducted with normal saline dilution of NovoLog ; therefore, the appropriateness of the use of diluted insulin for an individual patient should be determined by the treating physician. If you would like to order NovoLog diluent, please contact Novo Nordisk at The above information is supplied to you as a professional service in response to your specific request. Novo Nordisk does not recommend the use of its products in any manner other than as described in the prescribing information. About NovoLog NovoLog was developed for use as a mealtime (bolus) insulin. As compared to regular human insulin (RHI), subcutaneous injection of NovoLog provides a more rapid onset of action and a shorter duration of action. NovoLog is indicated for the treatment of patients with diabetes mellitus, for the control of hyperglycemia. Having an onset of action within minutes after subcutaneous injection, NovoLog should be administered at the beginning of a meal. NovoLog is normally used in regimens together with intermediate- or long-acting insulin. NovoLog may be infused subcutaneously by external insulin pumps. NovoLog may also be administered intravenously under proper medical supervision in a clinical setting for glycemic control. Hypoglycemia is the most common adverse effect of insulin therapy, including NovoLog. Additional information can be obtained at the web address, novolog.com. Page 3 of 5
4 About Novo Nordisk Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession, and society. Thank you for your interest in Novo Nordisk products. If you need any additional information, please do not hesitate to contact us at (800) Page 4 of 5
5 References 1. NovoLog [package insert]. Princeton, NJ: Novo Nordisk Inc.; Mar Jorgensen D, Solbeck H, Harboe E. Dilution of insulin aspart with NPH medium for small dose use in continuous subcutaneous insulin infusion does not affect in vitro stability. Diabetes. 2005; 54(suppl. 1):A Data on file at Novo Nordisk Inc. 4. Thilo E, Rosenberg A. The Newborn Infant. In: Hay W, LM, Sondheimer J, Deterding R, eds. Current Diagnosis & Treatment In Pediatrics. 18 The Mc Graw Hill Companies, Inc.; 2007: 5. Simeon PS. The premature infant with hyperglycemia: Use of continuous insulin infusions. The Journal of Perinatal and Neonatal Nursing. 1992; 6(1): Wintergerst KA, Hargadon S, Hsiang HY. Continuous subcutaneous insulin infusion in neonatal diabetes mellitus. Pediatr Diabetes. 2004; 5(4): Page 5 of 5
INSULIN PRODUCTS. Jack DeRuiter
INSULIN PRODUCTS Jack DeRuiter The number and types of insulin preparations available in the United States is constantly changing, thus students should refer to recent drug resources for a current list
More informationGuide for Storage of Insulin
Guide for Storage of Insulin Every effort is made to assure the accuracy of the attached information. This information is not intended to be used as a tool to prescribe medication or provide other clinical
More informationN HUMAN Novo Nordisk Patient Information for Novolin N
N HUMAN Novo Nordisk Patient Information for Novolin N NOVOLIN N (NO-voe-lin) NPH, Human Insulin Isophane Suspension Injection (recombinant DNA origin) 100 units/ml Important: Know your insulin. Do not
More informationIntensive Insulin Therapy in Diabetes Management
Intensive Insulin Therapy in Diabetes Management Lillian F. Lien, MD Medical Director, Duke Inpatient Diabetes Management Assistant Professor of Medicine Division of Endocrinology, Metabolism, & Nutrition
More information10 to 30 minutes ½ to 3 hours 3 to 5 hours. 30 60 minutes 1 to 5 hours 8 hours. 1 to 4 hours
Insulin Action There are several types of insulin. They are classified by how long they act: very fast, fast, slow and very slow acting. Each type of insulin has a certain time period in which it works.
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PC - Apidra, Levemir Therapeutic Class: Hormones and Synthetic Substitutes Therapeutic Sub-Class: Antidiabetic Agents Client: CA, CO, NV, OK, OR, WA and AZ Approval
More informationDetail-Document #190806. August 2003 ~ Volume 19 ~ Number 190806
Detail-Document #190806 August 2003 ~ Volume 19 ~ Number 190806 Insulins Lead author: Jill Allen, Pharm.D., BCPS A chart of insulin products and administration devices is located on pages three through
More informationDIABETES MEDICATION INSULIN
Section Three DIABETES MEDICATION INSULIN This section will tell you: About insulin. How to care and store your insulin. When to take your insulin. Different ways of taking insulin. WHAT IS INSULIN? Insulin
More informationINSULINThere are. T y p e 1 T y p e 2. many different insulins for
T y p e 1 T y p e 2 INSULINThere are many different insulins for Characteristics The three characteristics of insulin are: Onset. The length of time before insulin reaches the bloodstream and begins lowering
More informationStarting patients on the V-Go Disposable Insulin Delivery Device
Starting patients on the V-Go Disposable Insulin Delivery Device A simple guide for your practice For adult patients with Type 2 diabetes on basal insulin who need to take the next step Identify appropriate
More informationInsulin T Y P E 1 T Y P E 2
T Y P E 1 T Y P E 2 INSULIN There are many different insulins for many different situations and lifestyles. This section should help you and your doctor decide which insulin or insulins are best for you.
More informationInsulin: A Practice Update. Department of Nursing Staff Development Elizabeth Borgelt, MS, RN
Insulin: A Practice Update Department of Nursing Staff Development Elizabeth Borgelt, MS, RN Learning Outcome The learner will be able to identify the different types of insulins available, their actions,
More informationCLASS OBJECTIVES. Describe the history of insulin discovery List types of insulin Define indications and dosages Review case studies
Insulins CLASS OBJECTIVES Describe the history of insulin discovery List types of insulin Define indications and dosages Review case studies INVENTION OF INSULIN 1921 The first stills used to make insulin
More informationInsulin and Diabetes
Insulin What is Insulin? Insulin is a hormone produced by special cells in the pancreas These cells that are produced are called beta cells Insulin allows the glucose from food we eat to enter the cells
More informationUW MEDICINE PATIENT EDUCATION. Using Insulin. Basic facts about insulin and self-injection. What is insulin? How does diabetes affect the body?
UW MEDICINE PATIENT EDUCATION Using Insulin Basic facts about insulin and self-injection This handout explains what insulin is, the different types of insulin, how to store it, how to give an injection
More informationHumulin (HU-mu-lin) R
1 PATIENT INFORMATION Humulin (HU-mu-lin) R Regular U-500 (Concentrated) insulin human injection, USP (rdna origin) Read the Patient Information that comes with Humulin R U-500 before you start taking
More informationat The Valley Hospital (TVH) for Nursing Students/Nursing Instructors 2012
at The Valley Hospital (TVH) for Nursing Students/Nursing Instructors 2012 Subject - Insulin Safety Background Insulin known to be high risk medication Can promote serious hypoglycemia if given incorrectly
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PC (CO) - Insulin Delivery Systems Therapeutic Class: Hormones and Synthetic Substitutes Therapeutic Sub-Class: Insulin Delivery Systems Client: CO Approval Date:
More informationTypes of insulin and How to Use Them
Diabetes and Insulin Pumps Amy S. Pullen Pharm.D ISHP Spring Meeting April 2012 Objectives Describe the different types of insulin used in diabetes Identify the types of insulin that are compatible with
More informationContinuous Subcutaneous Insulin Infusion (CSII)
IMPORTANCE OF FOCUS CSII (Insulin pumps) have been used for more than 35 years. In the U.S. in 2005, the level of insulin pump penetration was estimated at 20 to 30% in patients with type 1 diabetes mellitus
More informationPackage Leaflet: Information for the user
Package Leaflet: Information for the user Actrapid 100 IU/ml solution for injection in vial Insulin human (rdna) Read all of this leaflet carefully before you start using your insulin Keep this leaflet.
More informationReducing the risk of patient harm: A focus on insulin
Reducing the risk of patient harm: A focus on insulin New York State Partnership for Patients (NYSPFP) Initiative Regional Educational Session November 2013 1 1 Disclosure Matt Fricker, Matt Grissinger,
More informationRECONSTITUTING MEDICATIONS: HOW TO FLUFF UP MEDICATIONS
RECONSTITUTING MEDICATIONS: HOW TO FLUFF UP MEDICATIONS After the completion of this module you will be able to: Define medication reconstitution. Read a medication label. Reconstitute a medication. Calculate
More informationInsulin Administration: What You Don t Know May Hurt Your Patient
Insulin Administration: What You Don t Know May Hurt Your Patient Jaime A. Davidson, MD, FACP, MACE Clinical Professor of Internal Medicine UT Southwestern Medical Center Dallas, Texas Jaime A. Davidson,
More informationIntroduction to Insulin. Your guide to taking insulin
Introduction to Insulin Your guide to taking insulin Introduction Insulin helps control the level of blood glucose in the body. Everyone with type 1 diabetes must take insulin, and many people with type
More informationHumulin R (U500) insulin: Prescribing Guidance
Leeds Humulin R (U500) insulin: Prescribing Guidance Amber Drug Level 2 We have started your patient on Humulin R (U500) insulin for the treatment of diabetic patients with marked insulin resistance requiring
More informationDiabetic patients treated with insulin,
Reviews/Commentaries/Position C O M M E N T A R Y Statements How Long Should Insulin Be Used Once a Vial Is Started? MARTIN M. GRAJOWER, MD 1 CHARLES G. FRASER, MS, PHARMD 2 JOHN H. HOLCOMBE, MD 3 MARCI
More informationReconstitution of Solutions
Chapter 12 Reconstitution of Solutions Reconstitution Process of mixing and diluting solutions Some medications supplied in powder form and must be mixed with liquid before administration Parts of Solutions
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Afrezza Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Afrezza (human insulin) Prime Therapeutics will review Prior Authorization requests Prior Authorization
More informationChapter 8 Insulin: Types and Activit y
Chapter 8 Insulin: Types and Activit y H. Peter Chase, MD Satish Garg, MD INSULIN Before insulin was discovered in 1921, there was little help for people who had type 1 diabetes. Since then, millions of
More informationTHE INS AND OUTS OF INSULIN. Mary Beth Wald, RN,BSN,CDE
THE INS AND OUTS OF INSULIN Mary Beth Wald, RN,BSN,CDE WHAT HAPPENS IN MY BODY? When we eat, the food gets changed into glucose, a type of sugar. Glucose travels in the blood to all the cells in your body
More informationINJEX Self Study Program Part 1
INJEX Self Study Program Part 1 What is Diabetes? Diabetes is a disease in which the body does not produce or properly use insulin. Diabetes is a disorder of metabolism -- the way our bodies use digested
More informationMedication Guide. SYMLIN (SĬM-lĭn) (pramlintide acetate) injection
Page 1 Medication Guide SYMLIN (SĬM-lĭn) (pramlintide acetate) injection Read the Medication Guide and the Patient Instructions for Use that come with your SYMLIN product before you start using it and
More informationGuidelines for Education and Training
Aim These protocols aim to provide the necessary guidance to enable insulin to be initiated safely and effectively Objectives 1. To provide the suggested procedure for the initiation of insulin for people
More informationOFFICE OF CATHOLIC SCHOOLS DIOCESE OF ARLINGTON DIABETES MEDICAL MANAGEMENT PLAN Page 1 of 5 TO BE COMPLETED BY PARENT OR GUARDIAN
PART I OFFICE OF CATHOLIC SCHOOLS DIOCESE OF ARLINGTON DIABETES MEDICAL MANAGEMENT PLAN Page 1 of 5 TO BE COMPLETED BY PARENT OR GUARDIAN Student School Date of Birth Date of Diagnosis Grade/ Teacher Physical
More informationInsulin human, rdna (produced by recombinant DNA technology in Saccharomyces cerevisiae).
Prescribing Information 1. NAME OF THE MEDICINAL PRODUCT INSULATARD vial 100 IU/ml Suspension for injection in a vial INSULATARD Penfill 100 IU/ml Suspension for injection in a cartridge 2. QUALITATIVE
More informationNew Zealand Consumer Medicine Information
New Zealand Consumer Medicine Information PenMix 30 100 IU/ml suspension for injection in cartridge PenMix 40 100 IU/ml suspension for injection in cartridge PenMix 50 100 IU/ml suspension for injection
More informationMANAGEMENT OF TYPE - 1 DIABETES MELLITUS
MANAGEMENT OF TYPE - 1 DIABETES MELLITUS INVESTIGATIONS AND TREATMENT MANSI NAIK VII SEMESTER INVESTIGATIONS FASTING BLOOD SUGAR PLASMA GLUCOSE HEMOGLOBIN A 1c SYMPTOMS OF TYPE 1 DIABETES MELLITUS Polyuria
More informationHIGHLIGHTS OF PRESCRIBING INFORMATION CONTRAINDICATIONS
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use NovoLog safely and effectively. See full prescribing information for NovoLog. NovoLog (insulin aspart
More informationALLERGENIC EXTRACT. Prescription Set of Serial Dilutions (or Maintenance Vial (s)) INSTRUCTIONS FOR USE. U.S. Government License No.
ALLERGENIC EXTRACT Prescription Set of Serial Dilutions (or Maintenance Vial (s)) INSTRUCTIONS FOR USE U.S. Government License No. 308 Revised 07/04 PO Box 800 Lenoir, NC 28645 USA DESCRIPTION This set
More informationDonovan Victorine Pharm.D. BCACP Clinical Pharmacy Specialist Boise VA Medical Center. U-500 Insulin
Donovan Victorine Pharm.D. BCACP Clinical Pharmacy Specialist Boise VA Medical Center U-500 Insulin Understand differences between U-500 concentrated insulin and standard insulin formulations Recognize
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES
MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Incretin Mimetic/Enhancer Hypoglycemics (formerly referred to as Other Hypoglycemics) A. Thresholds for Prior Authorization All prescriptions
More informationNovoLog Insulin aspart (rdna origin) Injection
Page 1 NovoLog Insulin aspart (rdna origin) Injection DESCRIPTION NovoLog (insulin aspart [rdna origin] injection) is a human insulin analog that is a rapidacting, parenteral blood glucose-lowering agent.
More informationScottish Medicines Consortium
Scottish Medicines Consortium insulin glulisine for subcutaneous injection 100 units/ml (Apidra ) No. (298/06) Sanofi Aventis 4 August 2006 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationPromoting safer use of injectable medicines
Promoting safer use of injectable medicines A template standard operating procedure for: prescribing, preparing and administering injectable medicines in clinical areas Introduction The use of injectable
More informationA list of all medications you are taking also include any vitamins, supplements, over-the-counter medicines, or herbal products
This is your customized insulin discussion guide to bring to your next doctor s visit. WHAT TO BRING TO YOUR NEXT CHECK UP A record of your recent blood sugar readings A list of all medications you are
More informationIndication: Posology: Indication: Posology:
Maklumat tambahan indikasi untuk upload pada laman web Year 2014 Products Approved For Additional Indication (DCA 275 9 Mei 2014) NO PRODUCT (ACTIVE INGREDIENT) 1. 1.1 Trajenta Duo 2.5mg/500mg Film-Coated
More informationInsulin Pump Therapy Is It Right for You? Compliments of Novo Nordisk Pharmaceuticals, Inc.
Insulin Pump Therapy Is It Right for You? Compliments of Novo Nordisk Pharmaceuticals, Inc. Who should consider the insulin pump option? More and more people with diabetes are switching from injecting
More informationDiabetes Medications: Insulin Therapy
Diabetes Medications: Insulin Therapy Courtesy Univ Texas San Antonio Eric L. Johnson, M.D. Department of Family and Community Medicine Diabetes and Insulin Type 1 Diabetes Autoimmune destruction of beta
More informationPerfalgan 10 mg/ml, solution for infusion
PACKAGE LEAFLET: INFORMATION FOR THE USER Perfalgan 10 mg/ml, solution for infusion Paracetamol Read all of this leaflet carefully before you start using this medicine. Keep this leaflet. You may need
More informationOnset Peak Duration Comments
Rapid- Acting 5-15 minutes 0.5-3 hours 3-5 hours Meal should be available before administering, ideally taking within 10 minutes of eating). Good in refrigerator (36-46 F) until expiration date. Protect
More informationNational Patient Safety Agency. Risk Assessment of Injectable Medicines. STEP 1 Local Risk Factor Assessment. STEP 2 Product Risk Factor Assessment
NPSA Injectable Medicines Risk Assessment Tool National Patient Safety Agency Risk Assessment of Injectable Medicines STEP 1 Local Risk Factor Assessment. Carry out a baseline assessment in a near patient
More informationGlycemic Control Initiative: Insulin Order Set Changes Hypoglycemia Nursing Protocol
Glycemic Control Initiative: Insulin Order Set Changes Hypoglycemia Nursing Protocol Ruth LaCasse Kalish, RPh Department of Pharmacy Objectives Review the current practice at UConn Health with sliding
More informationObjectives PERINATAL INSULIN PUMPS: BASICS FOR NURSES. Historical Perspective. Insulin Pumps in Pregnancy. Insulin Pumps in the US
Objectives PERINATAL INSULIN PUMPS: BASICS FOR NURSES Jo M. Kendrick, APN BC, CDE jkendric@utmck.edu Describe indications and contraindications for insulin pump use in hospitalized patients Differentiate
More informationDiabetes and Technology. Disclosures Certified Insulin Pump Trainer for: Animas Medtronic Diabetes Omnipod. Rebecca Ray, MSN, APRN, FNP-C
Diabetes and Technology Rebecca Ray, MSN, APRN, FNP-C Insulin Pump Therapy and Continuous Glucose Monitoring In Patients with Type 2 Diabetes Page 1 Disclosures Certified Insulin Pump Trainer for: Animas
More informationChapter 15. Reconstitution and Dosages Measured in Units. Copyright 2012, 2007 Mosby, Inc., an affiliate of Elsevier Inc. All rights reserved.
Chapter 15 Reconstitution and Dosages Measured in Units 1 Objectives Calculating drug dosage problems that first require reconstitution of a powdered drug into a liquid form Using a proportion to solve
More informationObjective. Failure Modes & Effects Analysis: A U-500 Insulin Case Study. What is a FMEA? Assembling a Team. Steps to Conducting a FMEA 5/12/2011
5/12/2011 Objective Failure Modes & Effects Analysis: A U-500 Insulin Case Study Understand the role of a failure mode and effects analysis (FMEA) in developing U-500 insulin use criteria Ryan J. Bickel,
More informationDiabetes Management Tube Feeding/Parenteral Nutrition Order Set (Adult)
Review Due Date: 2016 May PATIENT CARE ORDERS Weight (kg) Known Adverse Reactions or Intolerances DRUG No Yes (list) FOOD No Yes (list) LATEX No Yes ***See Suggestions for Management (on reverse)*** ***If
More informationBLOOD GLUCOSE MONITORING MEDICATION
DIABETES CARE FOR SCHOOL MEDICAL MANAGEMENT PLAN Most Recent A1C and Date: BLOOD GLUCOSE MONITORING Meter Type: Testing Independently: yes no Testing times: Before meals Two hours after insulin dosing
More informationALVIN INDEPENDENT SCHOOL DISTRICT Diabetes Medical Management Plan
ALVIN INDEPENDENT SCHOOL DISTRICT Diabetes Medical Management Plan of Plan: School Year (must be current): This plan should be completed by the student s personal health care team and parents/guardian.
More information[ ] POCT glucose Routine, As needed, If long acting insulin is given and patient NPO, do POCT glucose every 2 hours until patient eats.
Glycemic Control - Insulin Infusion NOTE: For treatment of Diabetic Ketoacidosis or Hyperglycemic Hyperosmolar Syndrome please go to order set named Diabetic Ketoacidosis (DKA) and Hyperglycemic Hyperosmolar
More informationHow To Store An Acam2000 Vaccine
ACAM2000 Smallpox (Vaccinia) Vaccine, Live Deployment Guidance - Acambis Inc. Revision: October 2008 Information contained in this guidance will also be available through Acambis, in the event that questions,
More informationBRIEFING 7 LABELING DEFINITION
Page 1 of 10 BRIEFING 7 Labeling. This general chapter provides definitions and standards for labeling of official articles. Note that, as with compendial quality standards, labeling requirements also
More informationImportant information on discontinuation of original Prefilled Pen containing Humalog Mix50/50
Important information on discontinuation of original Prefilled Pen containing Humalog Mix50/50 As of January 1, 2011, Eli Lilly and Company will no longer make the original Prefi lled Pen containing Humalog
More informationSTATE MEDICAID P&T COMMITTEE MEETING FRIDAY, November 16, 2007 7:00 a.m. to 8:30 a.m. Cannon Health Building Room 114 MINUTES
STATE MEDICAID P&T COMMITTEE MEETING FRIDAY, November 16, 2007 7:00 a.m. to 8:30 a.m. Cannon Health Building Room 114 Committee Members Present: Kort DeLost, R.Ph. David Harris, M.D. Koby Taylor, PharmD.
More informationROYAL HOSPITAL FOR WOMEN
ROYAL HOSPITAL FOR WOMEN LOCAL OPERATING PROCEDURE CLINICAL POLICIES, PROCEDURES & GUIDELINES Approved by Quality & Patient Safety Committee 17 April 2014 INSULIN INFUSION PROTOCOL INSULIN DEXTROSE INFUSION
More information13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 5 WARNINGS AND PRECAUTIONS. 14.1 Type 1 diabetes mellitus (adults) 5.
HIGHLIGHTS OF PRESCRIBING INFORMATION -----------------------WARNINGS AND PRECAUTIONS------------------------ These highlights do not include all the information needed to use Novolin Hypoglycemia: Most
More informationSECTION: NM NUMBER: 20. HENRY FORD HOSPITAL DETROIT, MICHIGAN TITLE: GLYCEMIC CONTROL INTENSIVE CARE PROTOCOL UNIT: All ICUs
CLINICALPROTOCOL MULTIDISCIPLINARY SECTION: NM NUMBER: 2 HENRY FORD HOSPITAL DETROIT, MICHIGAN TITLE: GLYCEMIC CONTROL INTENSIVE CARE PROTOCOL UNIT: All ICUs APPROVED: 3/3 REVIEWED: REVISED: 12/3, 5/,
More informationDiabetes and the Elimination of Sliding Scale Insulin. Date: April 30 th 2013. Presenter: Derek Sanders, D.Ph.
Diabetes and the Elimination of Sliding Scale Insulin Date: April 30 th 2013 Presenter: Derek Sanders, D.Ph. Background Information Epidemiology and Risk Factors Diabetes Its Definition and Its Impact
More informationYOUR GUIDE TO THE LANTUS SOLOSTAR INSULIN PEN
Important Safety Information for Lantus You must test your blood sugar levels while using insulin, such as Lantus. Do not make any changes to your dose or type of insulin without talking to your healthcare
More informationNovoLog (insulin aspart [rdna origin] injection) solution for subcutaneous use Initial U.S. Approval: 2000
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use NovoLog safely and effectively. See full prescribing information for NovoLog. NovoLog (insulin aspart
More informationPackage leaflet: Information for the user. Insulatard 100 international units/ml suspension for injection in vial human insulin
Package leaflet: Information for the user Insulatard 100 international units/ml suspension for injection in vial human insulin Read all of this leaflet carefully before you start using this medicine because
More informationNCT00272090. sanofi-aventis HOE901_3507. insulin glargine
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:
More informationPART III: CONSUMER INFORMATION. Important: Please Read
PART III: CONSUMER INFORMATION NovoRapid [vial/penfill / FlexPen /FlexTouch ] Important: Please Read Insulin Aspart Solution for Injection 10 ml / 3 ml This leaflet is Part III of a three-part Product
More informationby Rodney Lorenz, MD and Janet Silverstein, MD
Managing Insulin Requirements at School by Rodney Lorenz, MD and Janet Silverstein, MD Introduction Multiple advances over the past decade have revolutionized treatment of diabetes in youth. Two fundamental
More informationD( desired ) Q( quantity) X ( amount ) H( have)
Name: 3 (Pickar) Drug Dosage Calculations Chapter 10: Oral Dosage of Drugs Example 1 The physician orders Lasix 40 mg p.o. daily. You have Lasix in 20 mg, 40 mg, and 80 mg tablets. If you use the 20 mg
More informationA direction leaflet containing information for the patient is included in each package.
Novolin ge Penfill Premixed insulin preparations Insulin Injection 30% and Insulin Isophane 70% Insulin Injection 40% and Insulin Isophane 60% Insulin Injection 50% and Insulin Isophane 50% Human Biosynthetic
More informationInsulin Pens & Improving Patient Adherence
Insulin Pens & Improving Patient Adherence Bonnie Pepon, RN, BSN, CDE Certified Diabetes Educator Conemaugh Diabetes Institute Kip Benko, MD FACEP Asst Clinical Professor University of Pittsburgh School
More informationAbdulaziz Al-Subaie. Anfal Al-Shalwi
Abdulaziz Al-Subaie Anfal Al-Shalwi Introduction what is diabetes mellitus? A chronic metabolic disorder characterized by high blood glucose level caused by insulin deficiency and sometimes accompanied
More informationHealth Professions Act BYLAWS SCHEDULE F. PART 2 Hospital Pharmacy Standards of Practice. Table of Contents
Health Professions Act BYLAWS SCHEDULE F PART 2 Hospital Pharmacy Standards of Practice Table of Contents 1. Application 2. Definitions 3. Drug Distribution 4. Drug Label 5. Returned Drugs 6. Drug Transfer
More informationInstruction of 30/70 mixture Recombinant Human Insulin Injection
Instruction of 30/70 mixture Recombinant Human Insulin Injection Name: Generic Name: 30/70 mixture Recombinant Human Insulin Injection Commercial Name: Gansulin 30R (Dongbao Cartridge) English Name: 30/70
More informationINSULIN INJECTION KNOW-HOW
0-0- 0 INSULIN INJECTION KNOW-HOW pro tips (and tricks) for easier and better Insulin Injections ABDOMEN THIGHS BUTTOCKS ARMS recommended injection sites WHERE IS THE BEST PLACE TO GIVE INJECTIONS? 0-
More informationBy Lawrence A. Trissel, B.S., R.Ph., FASHP. Modified from the original presentation March 9, 2006
USP Chapter : Beyond Use Dating, Stability, and Storage Modified from the original presentation March 9, 2006 By Lawrence A. Trissel, B.S., R.Ph., FASHP Supported by an unrestricted educational grant
More informationBASAL BOLUS INSULIN FOR MEDICAL- SURGICAL INPATIENTS
BASAL BOLUS INSULIN FOR MEDICAL- SURGICAL INPATIENTS C O N T A C T D I A B E T E S S E R V I C E S F O R M O R E I N F O R M A T I O N 8 4 7-9 1 7-6 9 0 7 THIS SLIDE PRESENTATION WAS PREPARED BY SUE DROGOS,
More information50% INSULIN LISPRO PROTAMINE SUSPENSION AND 50% INSULIN LISPRO INJECTION (rdna ORIGIN) 100 UNITS PER ML (U-100)
1 HUMALOG Mix50/50TM 50% INSULIN LISPRO PROTAMINE SUSPENSION AND 50% INSULIN LISPRO INJECTION (rdna ORIGIN) 100 UNITS PER ML (U-100) DESCRIPTION Humalog Mix50/50 [50% insulin lispro protamine suspension
More informationSafe use of insulin e- learning module
Safe use of insulin e- learning module Page 1 Introduction Insulin is a hormone produced by the beta cells in the pancreas, it is released when blood glucose levels are raised for example after a meal.
More informationInsulin Lispro Solution Insulin Aspart Solution Insulin Glulisine Brand, Maker Humalog 19 Eli Lilly NovoLog, 20 Novo Nordisk b Apidra, 21,30 Aventis
Rapid-acting Detail-Document #220910!This Detail-Document accompanies the related article published in! PHARMACIST S LETTER / PRESCRIBER S LETTER September 2006 ~ Volume 22 ~ Number 220910 Comparison of
More informationby Rodney Lorenz, MD and Janet Silverstein, MD
Managing Insulin Requirements at School by Rodney Lorenz, MD and Janet Silverstein, MD Introduction Multiple advances over the past decade have revolutionized treatment of diabetes in youth. Two fundamental
More informationInjectable Insulin During Pregnancy
Injectable Insulin During Pregnancy What is insulin? Insulin is a hormone made by the pancreas. The pancreas is a small organ that lies behind and below the stomach. Insulin allows the food you eat to
More informationParenteral Dosage of Drugs
Chapter 11 Parenteral Dosage of Drugs Parenteral Route of administration other than gastrointestinal Intramuscular (IM) Subcutaneous (SC) Intradermal (ID) IV Parenteral Most medications prepared in liquid
More information3/25/11. Finding Ways Around High Dose Insulin Requirements: U-500 Insulin, Weight Loss, and Future Therapies. Outline of Talk.
Finding Ways Around High Dose Insulin Requirements: U-500 Insulin, Weight Loss, and Future Therapies Elaine K. Cochran, MSN, CRNP, BC-ADM National Institute of Diabetes and Digestive and Kidney Diseases
More informationResident s Guide to Inpatient Diabetes
Resident s Guide to Inpatient Diabetes 1. All patients with diabetes of ANY TYPE, regardless of reason for admission, must have a Hemoglobin A1C documented in the medical record within 24 hours of admission
More informationIntensifying Insulin Therapy
Intensifying Insulin Therapy Rick Hess, PharmD, CDE, BC-ADM Associate Professor Gatton College of Pharmacy, Department of Pharmacy Practice East Tennessee State University Johnson City, Tennessee Learning
More informationDear Parent/Guardian and Physician of
DIABETIC MANAGEMENT PLAN Parent Consent and Physician Authorization POWAY UNIFIED SCHOOL DISTRICT HEALTH SERVICES 15250 Avenue of Science San Diego CA 92128 Dear Parent/Guardian and Physician of California
More informationEverything You Wanted to Know about INSULIN!
Everything You Wanted to Know about INSULIN! What is Insulin? Life would not exist without insulin. In order to utilize the glucose (energy) found within the carbohydrate-laden foods we consume, insulin
More informationIntensifying Insulin In Type 2 Diabetes
Intensifying Insulin In Type 2 Diabetes Eric L. Johnson, M.D. Associate Professor Department of Family and Community Medicine University of North Dakota School of Medicine and Health Sciences Assistant
More informationNovoRapid is a modern insulin (insulin analogue) with a rapid acting effect. Modern insulin products are improved versions of human insulin.
Package leaflet: Information for the user NovoRapid FlexTouch 100 units/ml Solution for injection in pre filled pen Insulin aspart Read all of this leaflet carefully before you start using this medicine
More informationP A T I E N T I N F O R M A T I O N. Apidra
P A T I E N T I N F O R M A T I O N Apidra We have written this leaflet for those of you with diabetes who have been prescribed Apidra by your doctor. The primary goal of all diabetes treatment is to achieve
More informationThe Manitoba Pharmaceutical Association 200 TACHE AVENUE WINNIPEG, MANITOBA R2H 1A7 PHONE (204) 233-1411 FAX (204) 237-3468 E-Mail info@mpha.mb.
The Manitoba Pharmaceutical Association 200 TACHE AVENUE WINNIPEG, MANITOBA R2H 1A7 PHONE (204) 233-1411 FAX (204) 237-3468 E-Mail info@mpha.mb.ca Guidelines for the Pre-filling of Insulin Syringes Pharmacists
More informationAddressing safety concerns about U-500 insulin in a hospital setting
Addressing safety concerns about U-500 insulin in a hospital setting Karen Hamrick Samaan, Megan Dahlke, and Judy Stover U-500 regular insulin has been used since the 1950s to treat diabetic patients with
More information